JP2007520521A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520521A5
JP2007520521A5 JP2006551813A JP2006551813A JP2007520521A5 JP 2007520521 A5 JP2007520521 A5 JP 2007520521A5 JP 2006551813 A JP2006551813 A JP 2006551813A JP 2006551813 A JP2006551813 A JP 2006551813A JP 2007520521 A5 JP2007520521 A5 JP 2007520521A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dispersible pharmaceutical
spontaneously dispersible
nanoparticles
diluted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006551813A
Other languages
English (en)
Other versions
JP2007520521A (ja
Filing date
Publication date
Priority claimed from GBGB0402679.5A external-priority patent/GB0402679D0/en
Application filed filed Critical
Publication of JP2007520521A publication Critical patent/JP2007520521A/ja
Publication of JP2007520521A5 publication Critical patent/JP2007520521A5/ja
Pending legal-status Critical Current

Links

Description

本明細書で用いる「自発的に分散可能な医薬組成物」とは本明細書で定義する活性薬剤を含有し、そして水性溶媒、例えば水で希釈するか、または胃液中にある場合、コロイド構造を生成することができる組成物を意味する。コロイド構造は液滴およびナノ粒子を含む固体または好ましくは液体粒子でよい。自発的に分散可能な医薬組成物は好ましくはマイクロエマルジョン前濃縮物である。

JP2006551813A 2004-02-06 2005-02-04 特定のサブスタンスｐアンタゴニストを含んでなるマイクロエマルジョン製剤 Pending JP2007520521A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402679.5A GB0402679D0 (en) 2004-02-06 2004-02-06 Organic compounds
PCT/EP2005/001166 WO2005074891A1 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists

Publications (2)

Publication Number Publication Date
JP2007520521A JP2007520521A (ja) 2007-07-26
JP2007520521A5 true JP2007520521A5 (ja) 2008-03-21

Family

ID=31985813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551813A Pending JP2007520521A (ja) 2004-02-06 2005-02-04 特定のサブスタンスｐアンタゴニストを含んでなるマイクロエマルジョン製剤

Country Status (15)

Country Link
US (1) US20080254113A1 (ja)
EP (1) EP1715848B1 (ja)
JP (1) JP2007520521A (ja)
CN (1) CN1929817B (ja)
AT (1) ATE475409T1 (ja)
AU (1) AU2005210134B2 (ja)
BR (1) BRPI0507492A (ja)
CA (1) CA2553658A1 (ja)
DE (1) DE602005022558D1 (ja)
ES (1) ES2349647T3 (ja)
GB (1) GB0402679D0 (ja)
PL (1) PL1715848T3 (ja)
PT (1) PT1715848E (ja)
RU (1) RU2397759C2 (ja)
WO (1) WO2005074891A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
RU2481822C1 (ru) * 2012-02-21 2013-05-20 Автономная некоммерческая организация "Институт медико-биологических исследований и технологий" (АНО "ИМБИИТ") Микроэмульсионные композиции для создания трансдермальных и трансмукозальных форм фармацевтических средств и косметических препаратов и способ их получения
BR112015015864B1 (pt) * 2013-01-14 2022-08-23 Infirst Healthcare Limited Uso de uma composição farmacêutica no tratamento de uma condição de dor severa
CN105848643A (zh) * 2013-12-23 2016-08-10 强生消费者公司 消旋卡多曲组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
SK284579B6 (sk) * 1997-07-29 2005-07-01 Pharmacia & Upjohn Company Farmaceutická kompozícia pre lipofilné zlúčeniny
CN1216598C (zh) * 1998-08-25 2005-08-31 诺瓦提斯公司 药物用途
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
MY120392A (en) * 2000-06-08 2005-10-31 Hovid Berhad A novel drug delivery system : formulation for fat-soluble drugs

Similar Documents

Publication Publication Date Title
EP1712583A4 (en) POROUS CELLULOSE AGGREGATE AND FORMPRODUCT COMPOSITION THEREWITH
BRPI0512829A (pt) preparação de composições farmacêuticas contendo nanopartìculas
WO2009008923A3 (en) Methods of making nano-scale structures having controlled size, nanowire structures and methods of making the nanowire structures
JP2009516717A5 (ja)
WO2010041146A3 (en) Nanocomposite thermoelectric conversion material, thermoelectric conversion element including the same, and method of producing nanocomposite thermoelectric conversion material
JP2008526669A5 (ja)
EP1657289A3 (en) Semiconductor nanoparticle having high luminescence properties
JP2011500885A5 (ja)
JP2009504909A5 (ja)
WO2008074804A3 (en) Magnetic nanoparticles for the application in hyperthermia, preparation thereof and use in constructs having a pharmacological application
JP2007520521A5 (ja)
WO2009023304A3 (en) High density nanotube devices
JP2005509596A5 (ja)
WO2010102923A3 (en) Riluzole aqueous suspensions
JP2009522138A5 (ja)
WO2008005934A3 (en) Media sheet
WO2014174495A3 (en) An improved cosmetic composition
JP2013047264A5 (ja)
JP2008264777A5 (ja)
WO2008073731A3 (en) Microemulsion dosage forms of valsartan and methods of making the same
WO2006123354A3 (en) Oral pharmaceutical composition
JP2004534074A5 (ja)
JP2007063432A5 (ja)
JP2007022511A5 (ja)
RU2009101084A (ru) Способ получения высокодисперсных биологически активных материалов